Friday 9 August 2013

BBC Radio 4 - In Business, Gene Patenting

This is a very interesting debate and great plug for QuantuMDx Group Limited by our medical director Prof. Sir John Burn. I think Berwyn Clarke makes some valid points. This issue isn't as black and white as many people think. 

There must be a compromise!

"Ever since the mapping of the human genome was completed 10 years ago medical companies have been rushing to patent genes that define all of us for their own exclusive use. Now the US Supreme Court has ruled against patenting things found in nature. Peter Day asks what this means for the biotech business.and for the future of healthcare."


DNA Double Helix, courtesy
of BBC Radio 4

Thursday 8 August 2013

The QuantuMDx Story So Far - PART II




…. After the failure of our first business together, Elaine and I decided that we wanted to build a business of substance, rather than provide a service. This time the business was to be run and managed using our intuition, expertise and experience and not from any theories plied by a plethora of business schools or so called business experts. Above all the company had to be fun and motivating to work for. This was to be our baby and we were going to do it our way! 

The big idea...

Ever since my time at Harvard, I had been playing around with the idea of portable molecular diagnostic (MDx) and DNA Sequencing devices. I remembered reading in the Crimson about a Harvard Professor who had been able to detect the presence of DNA using tiny wires, or nanowires.

SEM of a bottom up nanowire
traversing two electrodes.
Detecting DNA using tiny silicon nanowires sounded like the coolest thing to me, more so that it was happening in a laboratory one building over from my lab.  I remember reading as much about them as possible and was honored to be at Harvard for the birth of such a great technology (and no, I am not talking about the Human Genome or Facebook, which also had its birth when I was there).

I delved into the literature and patents and ferociously read and absorbed as much as I could about them. It seemed clear to me that they where part of the puzzle I was constructing. Nanowire based biosensors can be produced in a standard CMOS fab, in great numbers and at low cost. They also operated label-free, without fluorescence, a big win as it meant that we didn’t need to use expensive fluorescent reagents or large and expensive detectors. Furthermore, they had been shown to have a ~10fM LOD and could be arrayed in their thousands (i.e. each sample could have 1000’s of tests done on it simultaneously). In short, it was the dream biosensor, multiplexed, cheap, scalable, super sensitive and small (perfect for a handheld).

The impressive wall of patents at Nanosys
As with most early stage companies in this space, securing your IP is the first job. We spoke to the great folk at Harvard Tech Transfer (one of the few university Tech Transfer offices that know what they are doing) and they put us in touch with a company in Palo Alto, CA, who had licensed all of Harvard’s nanowire technology.  I immediately flew out and pitched why they would want to exclusively license the nanowire technology to us in our field of DNA detection and sequencing. They agreed. Elaine followed up and negotiated a cracking deal for us and we used that to secure some initial funding that paid for the license.

We had a viable company!

A biosensor does not make a point of care (POC) molecular diagnostic device however, so with our license and the initial funding from an angel investor Julian (who has another role in Elaine’s life as private-life-husband. We joke that I am her professional husband as over the years we have had to spend a huge amount of time living together), we developed a coherent business plan, set up a laboratory in my garage (buying cheap equipment from e-bay among other vendors) and off we went.

The view from the 
Q-Apartment in Cape Town
Elaine went out and did the VC/Angel trail and held down several jobs to pay for the proof of principle data while I spent my days and nights testing technologies, ideas and reagents in my garage to pull together some initial proof of principle data that would support an argument for our vision of providing a multiplex MDx device. We incorporated the company on 4th March 2008 and on Xmas Eve 2008, whilst sipping champagne, we collectively signed the contracts on a multimillion pound investment deal from a state run investment fund in Cape Town, South Africa, for a joint venture.

QuantuMDx's lab in Tygerberg, SA
Part of the deal was that I would pack up, leave my family behind and move to Cape Town to set up the R&D facility and Elaine would set up the UK operations. So off we went and for 18 months it ran like a dream and we were very successful in all of our research and business.

Unfortunately one of the problems with government funds is that they can be taken away from you rather quickly and relatively easily. A reorganization of the regional funds saw a consolidation of not just the regional offices, but also of the projects they were willing to fund. We had demonstrated that we were on target and under budget, that our science was sound and technology was peer reviewed and viable, however they disputed the time to product that we claimed and as such we fell outside of their new criteria. It was a terrible day announcing the closure of the company and the imminent redundancy of the most amazing South African R&D team. The decision was hard to take at first, but in retrospect, that’s business and you just have to get on with it.

Elaine Warburton, entrepreneur
& business Rockstar!
And get on with it we did. I got back in my garage and started adding more data and wrote, with Elaine, some UK government grant applications. Fortunately, after going many months without a salary we successfully won one from i4i (part of the NIHR).

However, we still needed private investment to ensure we were a going concern and could provide the company contribution (UK grants are rarely 100% grants and require companies to match funds – a ridiculous situation that seems to favour larger companies). We walked the pavements of the city so many times and it was always the same story, too early, too late, too expensive, too inexperienced, etc, etc, a story I am sure most company owners will know well. It was soul destroying and utterly frustrating.

We were struggling with our finances, Elaine’s property was mortgaged to the hilt, mine was already in negative equity, all our savings had gone, the car was gone and we estimated that we were 11 days from calling in the liquidators, when we finally got our angel! Within a few days of successfully pitching to an a philanthropist we received a substantial investment hitting our account and we were back riding the rollercoaster! The deal was actually ‘inked’ over an iphone Skype call while Elaine and Julian were watching their youngest son score a 50 for County cricket. Rock n’ Roll!

Sir John Burn and I at the
Centre for Life
Upon getting the investment, our medical director (Professor Sir John Burn) managed to get us some space at the International Centre for Life in Newcastle upon Tyne, UK and I packed the garage lab into my car, along with some of my possessions and again left my family to pursue my dream.  I was kindly invited to stay at Sir Johns and once again built up the company from scratch.

We hired a few key positions, attracted more investment and grants (over £12m to date) and drove the development of our technology. As of today we have 40 staff (in 3 countries) working on our fully integrated bench top device that is capable of taking a whole blood sample through lysis, extraction, amplification and detection in under 15 minutes. Over the next 12 months we will miniaturize and speed up our bench top device so that it is palm sized and provides complex MDx analysis in under 10 minutes.


If nothing else, the above will tell you that we Quantumites (as we call ourselves) are a determined bunch and despite the shocking state of UK biosector funding, we don’t fail, nor will we fail in business or in our science. This blog will describe my personal journey as I ride the QuantuMDx rollercoaster. We are changing the world and saving millions of lives it really is that big!



The Q-Team outside our office


These are the personal words and opinions of Jonathan O’Halloran and do not reflect the opinion of QuantuMDx Group Limited.

Sunday 4 August 2013

The QuantuMDx Story So Far - PART I


So here it goes, my first blog of the new era of QuantuMDx Group. What better way to start, than to give you a brief history of me and the story of how the company started.

Lewes Old Grammar School
www.oldgrammar.e-sussex.sch.uk/
I guess the journey began back in 1991 at Lewes Old Grammar School, when at 16 years old, my wonderful Biology teacher (Dr Bishop) got hold of some Drosophila melanogaster strains from her daughter who was studying them in Cambridge at the time. Up until that point I was mildly interested with my studies and far more interested in playing football and spending hours making sure my hair was specifically arranged to ensure it looked like I had just got out of bed so that the girls I was chasing would be impressed that I didn’t care.

By the time the F2 progeny popped out of their eggs and I had counted the ratio of red, apricot, brown, carnation, and purple eyes I was hooked on genetics, partially because it demonstrated that I was red/green colour-blind, but mainly because that genetics experiment blew my mind.

My undergraduate university
After high school I enrolled in a one of the only straight genetics MSc programs in the country and fell in love with evolutionary theory, taught to me by the late John Maynard-Smith (He was instrumental in the application of game theory to evolution and theorized on other problems such as the evolution of sex and signaling theory), developmental genetics, bioinformatics and ultimately genomics. As a third year project I met Dr Janet Collet who took me under her wing and gave me the best education I could have ever hoped for. She showed me how to write, present, edit, design experiments, deal with politics, to fight for what I believed in and she even picked up the fact that I was dyslexic. Much of where I am and who I am today is down to Janet and I will be forever grateful to her.

It was Janet who invited me to spend the summer with her at Harvard University in 1997 and this eventually led to me spending a good number of years (1997-2001) at Harvard, during one of the most exciting periods in Genomics (the announcement of the sequencing of the first draft of the human genome) and also in the internet (the birth of Facebook). It was during a talk by Craig Venter in 1998 that I realized that I wanted to get into industry and set up my own company, one that could help humanity leverage the stunning work carried out by private and public efforts during the Human Genome Project.

Nuffield Hospital Tunbridge Wells
My one issue with making this dream a reality was that I knew a lot about fruit flies, but little about humans. So when I returned to the UK I took a technical role in a multidisciplinary pathology lab and set myself to learn as much as I could about the industry, diagnostics and business in general. I built labs and services for Immunology and Allergy and made that very successful, even winning an NHS contract. Then I set myself to doing the same for Molecular Diagnostics.

During the time I was helping John Roberts (the pathology laboratory manager who taught me so much about the industry & dealing with upper management – softly, softly, catchy monkey was his mantra to me) to set up the molecular diagnostics service, I was struck by how bad the technology was. I assume this was merely a function of its embryonic state, but it still bothered me that it was so fragmented and not pathology friendly. It was also apparent that people in healthcare really didn’t understand molecular biology and that there was significant opportunity to develop a service model to introduce for novel and new molecular assays.

I tried to get my superiors at the hospital group I was working at to buy into the idea, but as anyone who has worked for a big corporate machine knows, getting buy in for radical new ideas is a slow and frustrating process. I decided therefore to go it alone and began writing a business plan for a molecular laboratory with the husband (James Macrill) of one of my colleagues at the hospital group. James really challenged me and taught me a lot of what I needed to learn in terms of setting up a company.

My first letter to Elaine & my
first venture into entraprenuership
With business plan in hand, we set off to the city to do the usual rounds of VC and angel meetings. During one of these meetings, in a hotel in Tunbridge Wells, UK, we pitched our idea to Elaine Warburton, a director of The London Clinic on Harley Street, London (recently famous for treating Prince Phillip). The meeting went well and we all seemed to be on the same page with our vision for the future of Genetics and molecular diagnostics.

Unfortunately as time went on and the investors kept telling us we were too early, or too late, or not experienced enough, etc, etc and James had to make the hard decision to take work elsewhere and move on. This set back only served to push me on harder and when Elaine contacted me again to say she was putting together a company to provide Genetic Medicine services and clinics for early disease detection, surveillance and prevention and wanted me to join forces with her, I jumped at the opportunity.

Elaine & my first company together
Elaine had put together a very strong team and I took on the role of Bioscience Director – a novel role in which I advised on all aspects of the genetic and molecular testing, as well as searching the globe for new tests and technologies to bring into the company for us to distribute. We negotiated an exclusive license to distribute the Agendia portfolio of tests (including their MammaPrint breast cancer recurrence microarray), signed deals to operate clinics out of a number hospitals and off we went. Over the years I spent a lot of time traversing the globe meeting very smart people with amazing assays and technologies, both in academia and industry. It was the ultimate education in the global pipeline for molecular and genetic technology.

Unfortunately a combination of being too innovative, too early and differences of opinion regarding strategy at the board and investor level meant that the company was destined to fail. Close to the end Elaine and I resigned our positions as it was apparent that the company was not going down the route we wanted (it hadn’t invested in labs, technology and was purely providing low cost consultations and referring all tests to third parties – frankly impossible to make any money or investment returns of note).

After some time licking our wounds and learning the lessons that you can only get from business failure, we devised and incorporated our next company, QuantuMDx Group on 4th March 2008 …..

These are the personal words and opinions of Jonathon O’Halloran and do not reflect the opinion of QuantuMDx Group Limited.